PEB-Pacific Edge

[Left Field]

Interesting to see Harbour adding more at these levels. ( Mind you it's not their money.)

http://nzx-prod-s7fsd7f98s.s3-website-ap-southeast-2.amazonaws.com/attachments/PEB/413064/396507.pdf

[Basil]

Punters getting despondent (and with very good reason in my opinion), driving the price down 4.4% to 8.7 cps today.

[Left Field]

Seems like the release of PEB's FY23 AR today (and the comments contained in it) have not impressed the market,  (down to another 9% to 7.7c so far today.)

http://nzx-prod-s7fsd7f98s.s3-website-ap-southeast-2.amazonaws.com/attachments/PEB/413482/396909.pdf



 

[Teitei]

Seems like the release of PEB's FY23 AR today (and the comments contained in it) have not impressed the market,  (down to another 9% to 7.7c so far today.)

http://nzx-prod-s7fsd7f98s.s3-website-ap-southeast-2.amazonaws.com/attachments/PEB/413482/396909.pdf



 

They have had nearly a year's notice that the LCD coverage could be gone and the AR shows glaringly that they are totally un-prepared for the discontinuance.

Would you trust them with your money?

[LoungeLizard]

Seems like the release of PEB's FY23 AR today (and the comments contained in it) have not impressed the market,  (down to another 9% to 7.7c so far today.)

http://nzx-prod-s7fsd7f98s.s3-website-ap-southeast-2.amazonaws.com/attachments/PEB/413482/396909.pdf

True. Seems like an over-reaction to me, and at these levels it might be worth a punt. And yes, the phrase "good money after bad" does spring to mind. I can't see how the market could have expected any more than PEB laying out its options and looking to curb spending. The Novitas decision was so unexpected and so wide-reaching they need to carefully consider which option to take.
Interesting that one of the options was

d) consider other strategic alternatives, including partnerships with other large biotech businesses with strategic interests aligned with Pacific Edge.

I wonder if they have done any groundwork on this previously, or if it's a new thing brought on by the decision?
I think there's more to come from PEB on all of this, but by God, it's testing the limits of faith and patience.
 

[Left Field]

Agree, if I was the CEO of PEB I would be having discussions with the CEO of FPH for sure. FPH have considerable experience with; a.) USA medical approval processes. b.) USA Legal challenges and of course there are many other synergies eg sales force, research etc etc.

[BlackPeter]

Agree, if I was the CEO of PEB I would be having discussions with the CEO of FPH for sure. FPH have considerable experience with; a.) USA medical approval processes. b.) USA Legal challenges and of course there are many other synergies eg sales force, research etc etc.

Seriously - why would the CEO of a company like FPH be interested in talking with anybody at PEB? I hope he has more important things to do.

I suppose you realize as well, that both work in pretty different sections of the industry ... I'd imagine that the approval for a breathing apparatus is different to the approval of a bladder cancer test.

[LoungeLizard]

Seriously - why would the CEO of a company like FPH be interested in talking with anybody at PEB? I hope he has more important things to do.

I suppose you realize as well, that both work in pretty different sections of the industry ... I'd imagine that the approval for a breathing apparatus is different to the approval of a bladder cancer test.

Stranger things have happened - FPH might just look at it as an opportunity to get exposure to a new and developing filed of medicine. And the steps required to gain regulatory approval would not be dissimilar I wouldn't have thought. But it's unlikely that FPH would step in - more likely some other outfit in the Biomarking industry or even a more mainstream US based medical company with a few million to spare. I mean, despite this setback a lot of the major regulatory and industry hurdles have already been overcome. PEB may yet live to fight another day...   

[Left Field]

If BP is saying no one would waste their time to talk to PEB as he considers PEB a right-off, then that's his call and that's fine with me.

If BP is saying NZ CEO's don't work in collegial ways to sort out common issues, then that is not my experience.

I've seen many examples of NZ CEO's working together in the face of (say) unfair regulations, export opportunities etc.  NZ Trade missions are just one example.

[BlackPeter]

If BP is saying no one would waste their time to talk to PEB as he considers PEB a right-off, then that's his call and that's fine with me.

If BP is saying NZ CEO's don't work in collegial ways to sort out common issues, then that is not my experience.

I've seen many examples of NZ CEO's working together in the face of (say) unfair regulations, export opportunities etc.  NZ Trade missions are just one example.

LOL.

Seriously - do you have a problem to address the people you are talking to?

I am saying that I see very limited common ground for a company producing mechanical apparatuses to help patients with breathing and a company analysing biomarkers which might indicate a certain bladder cancer.

They would need to deal with completely different FDA procedures and departments.

But sure - maybe these green Martians land tomorrow in Dunedin and it turns out they have a huge need for breathing apparatuses equipped with biomarker analysis for bladder cancer. Suppose though, they would not insist on FDA approval, but as you say - stranger things might have happened before.

[Teitei]

Agree, if I was the CEO of PEB I would be having discussions with the CEO of FPH for sure. FPH have considerable experience with; a.) USA medical approval processes. b.) USA Legal challenges and of course there are many other synergies eg sales force, research etc etc.

PEB has spent tens of millions of dollars in the US on lawyers, consultants and highly paid staff to get somewhere and then, no where in recent times with the LCD withdrawal. Its advisory board over the years also had some high powered well connected individuals in the US (or so the company boasted).

Why and how would a company like FPH be able to add any value given the above?

Unless PEB is admitting that it has been using the wrong resources/advice/help in the last 10 years!

[Left Field]

PEB fighting on.

https://www.nzx.com/announcements/414089

Pacific Edge Chief Executive Dr Peter Meintjes said: "Despite the determination by Novitas, thousands of urologists across the US and around the world share our view that Cxbladder offers clinically valuable and actionable information. This information can improve the standard of care for patients suspected of or previously affected by bladder cancer, can offer improved patient management options for physicians, and spare patients from unnecessary invasive urinary tract examinations.

"When clinicians explain to patients that a Cxbladder test may allow them to safely avoid a cystoscopy, we expect many will accept some patient responsibility for payment if their insurer declines to cover the test".

"While the impact on demand for our tests in the US is uncertain, we expect the new approach to improve collections in the event of denial from any non-contracted insurer, including Medicare and make some contribution to revenues after 17 July."

[Basil]

Just the start of their dog and pony show to try and keep the dollars flowing to directors and management.
Expect a real big song and dance sometime next year with yet another capital raise....so many over the last 20 years I have lost count.

[winner (n)]

Seems like they are going to make the tests 'cheaper' so can keep throughput up.

Disc: Never been able fully understand what PEB are saying .....devil is in the detail.

[Left Field]

A stay of execution...... (Talk of legal action does wonders it would seem.)

https://www.nzx.com/announcements/414371

In an email received by Pacific Edge from our US lawyers, the US Department of Health and Human Services Associate General Counsel Janice L Hoffman said: "Details are being worked out but there is a commitment from these two MACs (same parent company) that the LCD will not proceed as is and that the LCD will go through the LCD process again with an open meeting and public comment period".

Those who bought "when there was blood on the streets" have done well.